Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trialVsevolod Matveev, Michiel S. van der Heijden, Matthew D. Galsky et al.|The Lancet Oncology|2020Cited by 502
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Cristiano Ferrario, Ronald de Wit et al.|The Lancet|2017Cited by 177
Robot‐assisted radical prostatectomy using hugo RAS system: The pioneer experience in Taiwan and Northeast AsiaYen‐Chuan Ou, Min‐Che Tung, Hsien‐Che Ou et al.|International Journal of Medical Robotics and Computer Assisted Surgery|2023Cited by 20
The Detection Performance of 18F–Prostate-Specific Membrane Antigen-1007 PET/CT in Primary Prostate CancerYa-Ting Huang, Yen‐Chuan Ou, Neng-Chuan Tseng et al.|Clinical Nuclear Medicine|2022Cited by 17
Building a Nomogram for Prediction of Prostate Cancer in Patients With Preoperatively Suspected Prostate CancerYen‐Chuan Ou, Tang‐Yi Tsao, KUANGH-HSI CHANG et al.|Anticancer Research|2020Cited by 8